Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 796 results for "lymphocyte count"

Clinical impact of peripheral lymphocyte counts for metastatic...

Pre-chemotherapeutic factors to assess the prognosis of patients with advanced urothelial carcinoma have not yet been completely established. Bladder Cancer Diagnosis Muscle Invasive / Metatastic Staging Pathology Guidelines ... UroToday, 2 weeks ago

CD4 T-Lymphocyte Percentages Corresponding to CD4 T-Lymphocyte Count Thresholds in a New Staging System for HIV Infection

JAIDS Journal of Acquired Immune Deficiency Syndromes. 66(4):e92-e94, August 1, 2014. Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). ...
 JAIDS1 month ago

Amgen: Grappling With The Reality Of Patent Expiries

Summary Amgen has been recently awarded the breakthrough status for its new drug to treat adults with acute lymphoblastic leukemia. The prevalence rate is quite high, with limited treatment options available. If authorized, Amgen can exploit the ...
 Seeking Alpha1 week ago
Reuters

Record-Breaking Year for The Leukemia & Lymphoma Society's Man & Woman of the Year campaign

-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- PR Newswire WHITE PLAINS, N.Y., July 17, 2014 WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962, ...
 Reuters1 week ago
[x]  
Examiner.com

Imbruvica gains breakthrough status for treating chronic lymphocytic leukemia

The FDA has expanded the use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), and thus have shown poor responses to standard treatment for the disease. The news ...
 Examiner.com9 hours ago IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p  Financial Content2 days ago 7/28/14 - IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p  Pharmacy Choice2 days ago IMBRUVICA? (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p  Applied Clinical Trials2 days ago
[x]  

Anakinra for Secondary Hemophagocytic Lymphohistiocytosis

Surender Rajasekaran, MD, MPH, Katherine Kruse, MD, Karen Kovey, PharmD, Alan T. Davis, PhD, Nabil E. Hassan, MD, Akunne N. Ndika, MBBS, MPH, Sandra Zuiderveen, BSN, RN, James Birmingham, MD Disclosures Pediatr Crit Care ...
 General Medicine eJournal1 month ago
Laboratory Network

Validation Study Of The Vi-CELL XR For Automated Cell Counting Of Dendritic Cells

By Iveta Bottova, PhD Dendritic cells (DC) population is a key functional constituent of cell based immunotherapy drugs. The correct cell count and adequate viability of DC are one of the quality control criteria for the final product release.
 Laboratory Network1 month ago

AbbVie releases interim results from Phase Ib trial of ABT-199/GDC-0199

AbbVie released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2, BCL-2, selective inhibitor, in combination with rituximab. Results showed an overall response rate, ORR, of 84%, in patients ...
 Yahoo! Finance1 month ago AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology...  Pharmacy Choice1 month ago
[x]  
Scottrade

Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia

/PRNewswire/ -- Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA) suggest continued durable responses in patients with treatment-naive (TN) or relapsed or refractory chronic lymphocytic leukemia ...
 BusinessWeek2 months ago Ibrutinib (IMBRUVICA?) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia  Applied Clinical Trials2 months ago Ibrutinib (IMBRUVICA??) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia  Review Seeker2 months ago Ibrutinib (IMBRUVICA(r)) Three Year Follow-up of Single-Agent and Combination  Finwin2 months ago
[x]  
4 Traders

U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the ...
 Red Orbit1 day ago Ibrutinib (IMBRUVICA(r)) RESONATE(tm) Data Show Significant Improvements in  Finwin2 months ago PHARMACYCLICS : U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications  4 Traders2 days ago Pharmacyclics: U.S. FDA Grants Regular Approval for Imbruvica  HispanicBusiness.com2 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less